BR0109919A - Proteìna, partìcula, molécula de ácido nucleico, célula hospedeira, processo para produzir uma proteìna, composição farmacêutica, uso de uma proteìna, e, método de vacinação profilática ou terapêutica de um indivìduo - Google Patents
Proteìna, partìcula, molécula de ácido nucleico, célula hospedeira, processo para produzir uma proteìna, composição farmacêutica, uso de uma proteìna, e, método de vacinação profilática ou terapêutica de um indivìduoInfo
- Publication number
- BR0109919A BR0109919A BR0109919-1A BR0109919A BR0109919A BR 0109919 A BR0109919 A BR 0109919A BR 0109919 A BR0109919 A BR 0109919A BR 0109919 A BR0109919 A BR 0109919A
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- particles
- loop
- hbcag
- sequences
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 8
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 102000004169 proteins and genes Human genes 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002255 vaccination Methods 0.000 title abstract 2
- 230000000069 prophylactic effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 101710132601 Capsid protein Proteins 0.000 abstract 7
- 239000000539 dimer Substances 0.000 abstract 2
- 238000003780 insertion Methods 0.000 abstract 2
- 230000037431 insertion Effects 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 210000000234 capsid Anatomy 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
"PROTEìNA, PARTìCULA, MOLéCULA DE áCIDO NUCLEICO, CéLULA HOSPEDEIRA, PROCESSO PARA PRODUZIR UMA PROTEìNA, COMPOSIçãO FARMACêUTICA, USO DE UMA PROTEìNA, E, MéTODO DE VACINAçãO PROFILáTICA OU TERAPêUTICA DE UM INDIVìDUO". O capsídeo de vírus de hepatite (HBV) é feito de uma única espécie de proteína chamada antígeno de núcleo (HBcAg) que se auto-reúne em partículas. As partículas são altamente imunogenes e são capazes de apresentar epítopos heterólogos ao sistema imune quando os epítopos são inseridos na região exposta das partículas à superfície chamada "laço el". Os blocos de construção estruturais das partículas são dímeros estreitamente associados de HBcAg em que os laços el adjacentes são intimamente justapostos. Propõe-se que as seq³ências inseridas no laço el sejam conformacionalmente limitadas nas partículas reunidas quando elas são apresentadas na proteína de núcleo monomérica. A invenção procura resolver este problema por ligação covalente das proteínas de núcleo como cópias em tandem, por exemplo como dímeros, de modo que as inserções podem ser feitas independentemente em cada cópia. Isto é particularmente utilizável para inserção de seq³ências grandes no laço el porque permite que estas seq³ências sejam inseridas em apenas uma cópia da proteína de núcleo por repetição em tandem, assim reduzindo a probabilidade de choques conformacionais em potencial na reunião. Alternativamente, uma diferente seq³ência pode ser inserida em cada laço el de uma repetição em tandem, assim aumentando a flexibilidade de partículas HBcAg como um sistema de liberação de epítopo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00107118 | 2000-04-07 | ||
PCT/GB2001/001607 WO2001077158A1 (en) | 2000-04-07 | 2001-04-09 | Hepatitis b core antigen fusion proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0109919A true BR0109919A (pt) | 2003-03-11 |
Family
ID=8168351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0109919-1A BR0109919A (pt) | 2000-04-07 | 2001-04-09 | Proteìna, partìcula, molécula de ácido nucleico, célula hospedeira, processo para produzir uma proteìna, composição farmacêutica, uso de uma proteìna, e, método de vacinação profilática ou terapêutica de um indivìduo |
Country Status (18)
Country | Link |
---|---|
US (1) | US7270821B2 (pt) |
EP (1) | EP1268530B1 (pt) |
JP (1) | JP4713809B2 (pt) |
KR (1) | KR100808313B1 (pt) |
CN (1) | CN100360556C (pt) |
AP (1) | AP1836A (pt) |
AT (1) | ATE336502T1 (pt) |
AU (1) | AU784345B2 (pt) |
BR (1) | BR0109919A (pt) |
CA (1) | CA2405438C (pt) |
DE (1) | DE60122300T2 (pt) |
DK (1) | DK1268530T3 (pt) |
EA (1) | EA200201077A1 (pt) |
ES (1) | ES2269371T3 (pt) |
MX (1) | MXPA02009895A (pt) |
PT (1) | PT1268530E (pt) |
WO (1) | WO2001077158A1 (pt) |
ZA (1) | ZA200208967B (pt) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60027581T2 (de) * | 1999-10-08 | 2007-05-10 | Celltech Pharma Europe Ltd., Slough | Design von immunogene |
US7128911B2 (en) | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
US7094409B2 (en) | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
AU2002339224B2 (en) | 2001-09-14 | 2008-10-09 | Kuros Us Llc | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
KR100465643B1 (ko) * | 2001-09-28 | 2005-01-13 | (주) 에이프로젠 | 비형 간염 바이러스 프리에쓰1 항원 유래의 에피토프 태그및 이에 대한 항체를 이용한 폴리펩티드의 검출 및 정제방법 |
MXPA04002644A (es) | 2001-10-05 | 2004-07-08 | Cytos Biotechnology Ag | Conjugados que portan un peptido de angiotensina y usos de los mismos. |
US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
JP5084103B2 (ja) | 2002-07-18 | 2012-11-28 | サイトス バイオテクノロジー アーゲー | ハプテン担体抱合体およびその用法 |
EP2338510A1 (en) | 2002-07-19 | 2011-06-29 | Novartis Pharma AG | Vaccine compositions containing amyloid beta1-6 antigen arrays |
EP1605973B1 (en) | 2003-03-26 | 2012-09-26 | Cytos Biotechnology AG | Packaging of immunostimulatory oligonucleotides into virus-like particles: methods of preparation and uses |
US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
CN100537762C (zh) * | 2004-06-24 | 2009-09-09 | 中国人民解放军军事医学科学院野战输血研究所 | 一种嵌合型病毒样颗粒疫苗载体蛋白及其制备方法与应用 |
KR100687653B1 (ko) * | 2005-05-13 | 2007-02-27 | 유기현 | 스타-델타 결선용 전자개폐기의 제어방법 |
WO2009022236A2 (en) | 2007-08-16 | 2009-02-19 | Tripep Ab | Immunogen platform |
WO2009130588A2 (en) * | 2008-04-22 | 2009-10-29 | Tripep Ab | Immunogen platform |
PE20110891A1 (es) | 2008-12-09 | 2011-12-23 | Pfizer Vaccines Llc | Vacuna de peptido ch3 de ige |
CN102596236B (zh) | 2009-07-30 | 2015-06-24 | 辉瑞疫苗有限责任公司 | 抗原性Tau肽及其用途 |
AU2010290931B2 (en) | 2009-09-03 | 2014-02-06 | Pfizer Vaccines Llc | PCSK9 vaccine |
GB0918679D0 (en) * | 2009-10-23 | 2009-12-09 | Iqur Ltd | Influenza vaccine |
EP2547695B1 (en) | 2010-03-16 | 2018-05-09 | Biontech Protein Therapeutics GmbH | Tumor vaccination involving a humoral immune response against self-protein cldn18.2 |
EP2942061A3 (en) | 2010-06-07 | 2016-01-13 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
US20140004142A1 (en) | 2011-03-02 | 2014-01-02 | Pfizer Inc. | Pcsk9 vaccine |
CN102199217B (zh) * | 2011-04-01 | 2013-03-27 | 中国人民解放军第三军医大学 | 乙型肝炎病毒多表位融合蛋白及其制备方法和应用 |
EP2698164B1 (en) | 2011-04-15 | 2018-04-04 | Osaka University | Dna vaccine |
JP6422022B2 (ja) * | 2012-08-31 | 2018-11-14 | 国立大学法人大阪大学 | Vegf及び/又はアンギオポエチン−2の特異的エピトープを含むdnaワクチン |
KR102237130B1 (ko) * | 2012-12-11 | 2021-04-08 | 오시벡스 에스에이에스 | 향상된 특성을 갖는 변형된 코일드 코일 유형 단백질 |
CN105431457A (zh) * | 2013-06-06 | 2016-03-23 | 大卫·J·罗兰 | 单结构域抗体展示 |
CN104341506A (zh) * | 2013-07-30 | 2015-02-11 | 复旦大学 | 一种重组融合蛋白及其用途 |
US10279019B2 (en) | 2014-02-11 | 2019-05-07 | Stc.Unm | PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same |
GB201402890D0 (en) * | 2014-02-18 | 2014-04-02 | Iqur Ltd | Vaccines based on hepatitis B Core antigens |
GB201421692D0 (en) * | 2014-12-05 | 2015-01-21 | Iquar Ltd | Vaccines based on hepatitis B core antigens |
GB201505041D0 (en) * | 2015-03-25 | 2015-05-06 | Iqur Ltd | Vaccines based on hepatitis B core antigens |
BR112019009221A2 (pt) | 2016-11-11 | 2019-07-16 | Fraunhofer Usa Inc | proteína de fusão, método para produzir a proteína, composição, partícula semelhante a vírus, método para produzir partículas semelhantes a vírus, e método para induzir uma resposta imunológica em um sujeito |
CN110343707B (zh) * | 2019-05-30 | 2021-06-15 | 中国科学院生物物理研究所 | 基于乙肝核心抗原的hsv分型用蛋白、试剂盒及方法和应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2480780B1 (fr) * | 1980-04-22 | 1985-12-06 | Pasteur Institut | Procede de transformation de cellules, notamment eucaryotes, par un adn circulaire tel que celui du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn |
JP2514033B2 (ja) * | 1987-05-20 | 1996-07-10 | 財団法人 癌研究会 | B型肝炎ウィルスの複製を可能とする新規な培養細胞 |
NZ235315A (en) * | 1989-09-19 | 1991-09-25 | Wellcome Found | Chimaeric hepadnavirus core antigen proteins and their construction |
US5723129A (en) * | 1991-10-16 | 1998-03-03 | University Of Saskatchewan | GnRH-leukotoxin chimeras |
JPH06279500A (ja) * | 1992-09-30 | 1994-10-04 | Imuno Japan:Kk | HBc融合蛋白粒子およびその製造方法 |
WO1997035008A1 (en) * | 1996-03-21 | 1997-09-25 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods and compositions of chimeric polypeptides for tumor antigen vaccines |
US20030021804A1 (en) * | 1997-01-21 | 2003-01-30 | Philip Needleman | Immunological process for increasing the hdl cholestrol concentration |
US6172216B1 (en) * | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
US6180343B1 (en) * | 1998-10-08 | 2001-01-30 | Rigel Pharmaceuticals, Inc. | Green fluorescent protein fusions with random peptides |
DE60027581T2 (de) * | 1999-10-08 | 2007-05-10 | Celltech Pharma Europe Ltd., Slough | Design von immunogene |
DK1294893T3 (da) * | 2000-06-22 | 2006-07-03 | Ucb Pharma Ltd | Modifikation af hepatitis B-kerneantigen |
US7351413B2 (en) * | 2002-02-21 | 2008-04-01 | Lorantis, Limited | Stabilized HBc chimer particles as immunogens for chronic hepatitis |
-
2001
- 2001-04-09 EA EA200201077A patent/EA200201077A1/ru unknown
- 2001-04-09 WO PCT/GB2001/001607 patent/WO2001077158A1/en active IP Right Grant
- 2001-04-09 AU AU46706/01A patent/AU784345B2/en not_active Ceased
- 2001-04-09 CA CA2405438A patent/CA2405438C/en not_active Expired - Fee Related
- 2001-04-09 KR KR1020027013451A patent/KR100808313B1/ko not_active IP Right Cessation
- 2001-04-09 JP JP2001575628A patent/JP4713809B2/ja not_active Expired - Fee Related
- 2001-04-09 PT PT01919645T patent/PT1268530E/pt unknown
- 2001-04-09 BR BR0109919-1A patent/BR0109919A/pt not_active IP Right Cessation
- 2001-04-09 DK DK01919645T patent/DK1268530T3/da active
- 2001-04-09 MX MXPA02009895A patent/MXPA02009895A/es active IP Right Grant
- 2001-04-09 CN CNB018106889A patent/CN100360556C/zh not_active Expired - Fee Related
- 2001-04-09 US US10/240,917 patent/US7270821B2/en not_active Expired - Fee Related
- 2001-04-09 AT AT01919645T patent/ATE336502T1/de active
- 2001-04-09 DE DE60122300T patent/DE60122300T2/de not_active Expired - Lifetime
- 2001-04-09 ES ES01919645T patent/ES2269371T3/es not_active Expired - Lifetime
- 2001-04-09 AP APAP/P/2002/002658A patent/AP1836A/en active
- 2001-04-09 EP EP01919645A patent/EP1268530B1/en not_active Expired - Lifetime
-
2002
- 2002-11-05 ZA ZA200208967A patent/ZA200208967B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20040223965A1 (en) | 2004-11-11 |
US7270821B2 (en) | 2007-09-18 |
CA2405438C (en) | 2011-07-12 |
KR20030009429A (ko) | 2003-01-29 |
DE60122300D1 (de) | 2006-09-28 |
DK1268530T3 (da) | 2006-11-13 |
AU784345B2 (en) | 2006-03-16 |
CA2405438A1 (en) | 2001-10-18 |
MXPA02009895A (es) | 2004-09-06 |
ZA200208967B (en) | 2003-10-08 |
CN1441807A (zh) | 2003-09-10 |
KR100808313B1 (ko) | 2008-02-27 |
AU4670601A (en) | 2001-10-23 |
WO2001077158A1 (en) | 2001-10-18 |
JP2003530123A (ja) | 2003-10-14 |
CN100360556C (zh) | 2008-01-09 |
DE60122300T2 (de) | 2007-08-30 |
ES2269371T3 (es) | 2007-04-01 |
EP1268530A1 (en) | 2003-01-02 |
PT1268530E (pt) | 2006-12-29 |
JP4713809B2 (ja) | 2011-06-29 |
ATE336502T1 (de) | 2006-09-15 |
EA200201077A1 (ru) | 2003-04-24 |
EP1268530B1 (en) | 2006-08-16 |
AP2002002658A0 (en) | 2002-12-31 |
AP1836A (en) | 2008-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0109919A (pt) | Proteìna, partìcula, molécula de ácido nucleico, célula hospedeira, processo para produzir uma proteìna, composição farmacêutica, uso de uma proteìna, e, método de vacinação profilática ou terapêutica de um indivìduo | |
ATE159031T1 (de) | Antigene sowie verfahren zu deren herstellung | |
Hauser et al. | Immunological properties of recombinant HBsAg produced in yeast. | |
EA200100425A1 (ru) | Новые способы терапевтической вакцинации | |
BR9905902A (pt) | Clone de cdna infeccioso do vìrus da sìndrome reprodutiva e respiratória de porcino norte-americana (prrs) e seus usos | |
BR0113307A (pt) | Molécula de proteìna quimérica de núcleo de vìrus de hepatite b recombinante, partìcula imunogênica, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, célula hospedeira e método de induzir uma resposta imunológica em um animal hospedeiro inoculado | |
PT97159A (pt) | Processo para a preparacao de uma proteina do antigenio de superficie da hepatite b ou de um seu fragmento e processo para a preparacao de uma vacina | |
Morein et al. | Protein subunit vaccines of parainfluenza type 3 virus: immunogenic effect in lambs and mice | |
US4547368A (en) | Hepatitis B core antigen vaccine made by recombinant DNA | |
Palese et al. | Development of novel influenza virus vaccines and vectors | |
CN103768595A (zh) | 唑来膦酸佐剂及含唑来膦酸佐剂的疫苗 | |
WO2006045532A2 (en) | Virosome particles comprising antigens from influenza virus and hepatitis b virus | |
Chang et al. | A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus | |
BR0112020A (pt) | Partìculas tipo vìrus de bvdv | |
Xu et al. | Long-term immunogenicity of an inactivated split-virion 2009 pandemic influenza A H1N1 virus vaccine with or without aluminum adjuvant in mice | |
JP7403733B2 (ja) | インフルエンザhaスプリットワクチンの製造方法 | |
Howard et al. | Preparation and properties of immune-stimulating complexes containing hepatitis B virus surface antigen | |
CA1292690C (en) | Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic sequentially homologous peptide | |
DE68926274D1 (de) | Rekombinante HBsAg Hybridpartikel, die morphologische Eigenschaften von HBsAg-Antigen haben und eine immunogene Sequenz enthalten, die neutralisierende Antikörper gegen HIV induziert oder die von diesen Antikörpern erkannt ist, Nukleotide Sequenzen, die diese Partikel codieren und sie enthaltende Impfstoffe | |
Rappuoli | Cell-culture-based vaccine production: technological options | |
Huang et al. | New advances in hepatitis B vaccination for adults | |
US9603921B2 (en) | Virosome particles comprising antigens from influenza virus and hepatitis b virus | |
Laver et al. | Preparation and immunogenicity of a purified influenza virus haemagglutinin and neuraminidase subunit vaccine | |
CN102199217A (zh) | 乙型肝炎病毒多表位融合蛋白及其制备方法和应用 | |
JP2002513771A (ja) | 新規組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07F | Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette] |
Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |